AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis Google Miscellanea

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis Google Miscellanea

22 March 2021 07:00 GMT  79% vaccine efficacy at preventing symptomatic COVID-19100% efficacy against severe or critical disease and hospitalisation Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favourable reactogenicity and overall safety profile   The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant […]